RecruitingPhase 3NCT04116502
MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera
A Phase III, Randomised, Open-label, Multicenter International Trial Comparing Ruxolitinib With Either HydRoxycarbamIDe or Interferon Alpha as First Line ThErapy for High Risk Polycythemia Vera
Sponsor
University of Birmingham
Enrollment
586 participants
Start Date
Oct 25, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
The trial will be a phase III, randomised-controlled, multi-centre, international, open-label trial consisting of ruxolitinib versus best available therapy, where best available therapy is a choice of interferon alpha, any formulation permitted (IFN) or hydroxycarbamide (HC), and which will be elected by the Investigator prior to randomisation.
Eligibility
Min Age: 18 Years
Inclusion Criteria13
- Population:
- High risk PV defined as WBC \>11 x 10\^9/l\* AND at least ONE of the following
- Age \>60 years
- Prior thrombosis or haemorrhage
- Platelet count \>1000 x 10\^9/l\*
- Hypertension or diabetes requiring pharmacological therapy (\*At any time since diagnosis)
- Patient ≥18 years of age
- Diagnosis of PV meeting the WHO criteria within the past 15 years
- Meets criteria of high risk\* PV (see above for specific population)
- Patients must have a screening haemoglobin of \>8g/dl
- Patients may have received antiplatelet agents and venesection
- Patients may have received ONE cytoreductive therapy for PV less than 10 years (BUT they should not be resistant or intolerant to that therapy)
- Able to provide written informed consent
Exclusion Criteria23
- Diagnosis of PV \> 15 years previously
- Absence of JAK-2 mutation
- Patients with any contraindications to any of the investigational medical products
- Treatment with \>1 cytoreductive therapy OR a cytoreductive treatment duration exceeding 10 years OR resistance/intolerance to that therapy
- Active infection including Human Immunodeficiency Virus (HIV), hepatitis B, hepatitis C, autoimmune hepatitis, Tuberculosis
- Pregnant or lactating patients (Women of childbearing potential must have a negative urine or blood Human Chorionic Gonadotropin pregnancy test prior to trial entry)
- Patients with lactose allergies, hypersensitivities, or rare hereditary problems, of galactose intolerance, total lactase deficiency or glucose- galactose malabsorption
- Patients with uncontrolled neuropsychiatric disorders
- Patients with uncontrolled cutaneous cancers
- Patients and partners not prepared to adopt highly effective contraception measures (if sexually active) whilst on treatment and for at least 6 months after completion of study medication
- ECOG Performance Status Score ≥ 3
- Uncontrolled rapid or paroxysmal atrial fibrillation, uncontrolled or unstable angina, recent (within the last 6 months) myocardial infarction or acute coronary syndrome or any clinically significant cardiac disease \> NYHA ( New York Heart Association) Class II
- Patients who have transformed to myelofibrosis
- Previous treatment with ruxolitinib
- Previous (within the last 12 months) or current platelet count \<100 x 109/L or neutrophil count \< 1 x 109/L not due to therapy
- Inadequate liver function as defined by ALT/AST \>2.0 x ULN
- Inadequate renal function as defined by eGFR \< 30 mls/min
- Unable to give informed consent
- All women of childbearing potential (as per Appendix 8 definition)
- No affiliation with the French healthcare system
- Persons under psychiatric care that would impede understanding of informed consent and optimal treatment and follow-up
- Adults subject to a legal protection measure (guardianship, curatorship and safeguard of justice)
- Patients deprived of their liberty by a judicial or administrative decision
Interventions
DRUGRuxolitinib
10mg of ruxolitinib twice daily (bd)
DRUGHydroxycarbamide
Via standard hospital mechanisms
DRUGInterferon-Alpha
Any formulation, via standard hospital mechanisms
Locations(47)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04116502
Related Trials
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
NCT042821871 location
Two Step Haplo With Radiation Conditioning
NCT050318971 location
A Study of GLB-001 in Patients With Myeloid Malignancies
NCT0637843714 locations
Myeloproliferative Neoplasms (MPNs) Patient Registry
NCT027602381 location
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
NCT062186281 location